CAS · 112901-68-5
Product Overview
Amifostine丨CAS 112901-68-5 is a prodrug designed to protect normal tissues from the toxic effects of chemotherapy and radiation therapy. It was originally developed by the Walter Reed Army Institute of Research and later commercialized as a drug to reduce the side effects of cancer treatments.
Amifostine works by selectively scavenging reactive oxygen species (ROS) and detoxifying harmful metabolites generated by radiation or chemotherapy, thereby protecting normal cells without reducing the efficacy of cancer treatment.
Product Specifications
| Appearance | White crystal powder |
|---|---|
| Assay (C5H15N2O3PS) | 78-82% min |
| Identification | HPLC, IR Complies |
| pH | 6.5 - 7.5 |
| Water | 19.2% - 21.2% |
| Heavy metals | 20 ppm max |
| Total impurities | 0.3% max |
| Individual impurity | 0.1% max |
| Amifostine thiol | 0.3% max |
Applications
1. Radiation Therapy Protection
Amifostine丨CAS 112901-68-5 is FDA-approved to reduce radiation-induced xerostomia (dry mouth) in patients undergoing radiation treatment for head and neck cancers.
Protects salivary glands from radiation damage
Reduces symptoms like dry mouth, difficulty swallowing, and oral mucositis
Improves patient quality of life during and after radiation therapy
2. Chemotherapy Toxicity Reduction
Used to reduce cisplatin-induced nephrotoxicity (kidney damage):
Cisplatin is a potent chemotherapy drug but can cause severe renal toxicity.
Amifostine protects renal tubular cells by scavenging harmful platinum metabolites.
Enables higher or more frequent cisplatin dosing with fewer side effects.
Additionally, Amifostine may reduce toxicity from other alkylating agents and platinum-based drugs.
3. Bone Marrow Protection
Amifostine provides some myeloprotective effects, reducing bone marrow suppression from chemotherapy, allowing for better patient tolerance to treatment.
4. Experimental and Investigational Uses
Studied for protection against radiation exposure in non-cancer settings (e.g., accidental radiation exposure or space travel)
Investigated in combination therapies to reduce toxicities of other anticancer agents
Potential neuroprotective roles in neurodegenerative diseases or stroke
Benefits
1. Selective Cytoprotection
Protects normal tissues without interfering with tumor cell killing, due to selective activation.
Minimizes adverse effects, improving patient adherence and comfort.
2. Improved Therapeutic Index
Allows higher doses or intensified treatment schedules of radiation and chemotherapy by reducing dose-limiting toxicities.
Can potentially improve treatment outcomes indirectly by enabling more aggressive therapy.
3. Quality of Life Improvement
Reduces debilitating side effects such as dry mouth, which affects speech, taste, and oral hygiene.
Protects kidneys and bone marrow, reducing hospitalization and supportive care needs.
Conclusion
A concise summary and suitability assessment for this product is available on request. Contact our team to discuss whether it fits your process and quality requirements.